Evidence map›Paper›PMID 24824408›Full record

ArticleUrology2014

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

William D Figg, Cindy H Chau, Douglas K Price, Cathee Till, Phyllis J Goodman, Yonggon Cho, Marileila Varella-Garcia, Juergen K V Reichardt, Catherine M Tangen, Robin J Leach and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Height, Obesity, and the Risk ofCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

William D FiggGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address: figgw@helix.nih.gov.
Cindy H ChauGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Douglas K PriceGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Cathee TillSWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Phyllis J GoodmanSWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Yonggon ChoChonbuk National University Medical School, Jeonju, South Korea.
Marileila Varella-GarciaDepartment of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
Juergen K V ReichardtSchool of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia.
Catherine M TangenSWOG Statistical Center, the Fred Hutchinson Cancer Research Center, Seattle, WA.
Robin J LeachDepartment of Urology and Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Adrie van BokhovenDepartment of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
Ian M ThompsonDepartment of Urology and Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.
M Scott LuciaDepartment of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.
Fred Hutch Cancer Center · USNational Cancer Institute · USUniversity of Colorado Denver · USThe University of Texas Health Science Center at San Antonio · USJames Cook University · AUJeonbuk National University · KR

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Oxidative Damage and DNA Repair in the PCPTP01CA108964 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, IAN M · 2005 to 2009
$13.6M
Identify SNPs and Polymorphisms Involved in the Development of Prostate CancerZIABC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$10.4M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
SNPs /Polymorphisms in Development of Prostate CancerZ01BC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2002 to 2008
$938k
Intramural NIH HHS ZIA BC010453NCI NIH HHS CA37429NCI NIH HHS P01 CA108964NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA054174NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NCI NIH HHS ZO1 BC010453
6 · The paper itself

Abstract

objectiveTo investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes.

methodsThis nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls.

resultsThere was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease.

conclusionOur findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.

Indexed as

Trinucleotide RepeatsCase-Control StudiesHumansMaleMiddle AgedProstatic NeoplasmsProto-Oncogene Proteins c-etsReceptors, AndrogenRisk FactorsSerine EndopeptidasesAR protein, humanProto-Oncogene Proteins c-etsReceptors, AndrogenSerine EndopeptidasesTMPRSS2 protein, human

Identifiers

PMID24824408
PMCPMC4077907
OpenAlexW2027164537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.